First left-right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex.

@article{Tanaka2013FirstLC,
  title={First left-right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex.},
  author={Masaaki Tanaka and Mari Wataya-Kaneda and Ayumi Nakamura and Shoji Matsumoto and Ichiro Katayama},
  journal={The British journal of dermatology},
  year={2013},
  volume={169 6},
  pages={1314-8}
}
BACKGROUND Tuberous sclerosis complex (TSC) is an autosomal dominant disorder causing multiple hamartomas. Treatment of TSC lesions with mammalian target of rapamycin inhibitors is effective. Recently, several reports have shown the efficacy of topical rapamycin (sirolimus) for angiofibromas. However, almost all studies have been case studies and the 0·1% solution caused skin irritation. A comparative study of topical rapamycin and a vehicle has not yet been reported. OBJECTIVES To compare… CONTINUE READING